Mecasermin rinfabate is under clinical development by Oak Hill Bio and currently in Phase II for Retinopathy Of Prematurity. According to GlobalData, Phase II drugs for Retinopathy Of Prematurity have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mecasermin rinfabate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mecasermin rinfabate overview

Mecasermin rinfabate (Iplex) is a recombinant human biologic protein complex of insulin-like growth factor-1 (IGF-1). It is formulated as injectable solution for subcutaneous route of administration. It is indicated in the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD).

Mecasermin rinfabate (Iplex) is under development for treatment of chronic respiratory morbidity (CRM) including bronchopulmonary dysplasia (BPD), retinopathy of prematurity and severe intraventricular hemorrhage. It was also under development for the treatment of burns, myotonic dystrophy, Rabson–Mendenhall syndrome, Leprechaunism, laron syndrome, type A and type B extreme insulin resistance syndrome.

Oak Hill Bio overview

Oak Hill Bio is a neonatology and rare disease therapeutics company that discovers and develops medicines for rare autoimmune diseases. The company is investigating OHB-607, a recombinant version of insulin-like growth factor 1 (IGF-1) to treat bronchopulmonary dysplasia; OHB-101 programs targeting immune thrombocytopenia and IgA nephropathy; OHB-401 drug against diabetic macular edema. It is also evaluating OHB-201, OHB-211, and OHB-301 programs for the treatment of autoimmune diseases. The company has operations in the US and the UK. Oak Hill Bio is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Mecasermin rinfabate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.